- Home
- EXK vs GYRE Comparison
EXK vs GYRE Comparison
Compare EXK & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXK
- GYRE
- Stock Information
- Founded
- EXK 1981
- GYRE 2002
- Country
- EXK Canada
- GYRE United States
- Employees
- EXK N/A
- GYRE N/A
- Industry
- EXK Precious Metals
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- EXK Basic Materials
- GYRE Health Care
- Exchange
- EXK Nasdaq
- GYRE Nasdaq
- Market Cap
- EXK 949.5M
- GYRE 897.1M
- IPO Year
- EXK N/A
- GYRE N/A
- Fundamental
- Price
- EXK $5.06
- GYRE $7.46
- Analyst Decision
- EXK Strong Buy
- GYRE
- Analyst Count
- EXK 3
- GYRE 0
- Target Price
- EXK $6.83
- GYRE N/A
- AVG Volume (30 Days)
- EXK 17.0M
- GYRE 232.6K
- Earning Date
- EXK 07-31-2025
- GYRE 08-12-2025
- Dividend Yield
- EXK N/A
- GYRE N/A
- EPS Growth
- EXK N/A
- GYRE N/A
- EPS
- EXK N/A
- GYRE 0.02
- Revenue
- EXK $217,412,000.00
- GYRE $100,643,000.00
- Revenue This Year
- EXK $99.18
- GYRE $21.04
- Revenue Next Year
- EXK $49.21
- GYRE $89.64
- P/E Ratio
- EXK N/A
- GYRE $93.77
- Revenue Growth
- EXK 1.72
- GYRE N/A
- 52 Week Low
- EXK $2.46
- GYRE $6.11
- 52 Week High
- EXK $5.67
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- EXK 67.36
- GYRE 36.76
- Support Level
- EXK $4.66
- GYRE $7.14
- Resistance Level
- EXK $4.95
- GYRE $7.80
- Average True Range (ATR)
- EXK 0.21
- GYRE 0.49
- MACD
- EXK -0.02
- GYRE -0.06
- Stochastic Oscillator
- EXK 80.30
- GYRE 0.48
About EXK Endeavour Silver Corporation (Canada)
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has two operating mining segments which are located in Mexico, Guanacevi and Bolanitos. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.